Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC
Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...
Clinical trial results
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...
Clover Biopharma’s SCB-2019 Vaccine Shows Strong Immune Response to Omicron BA.5
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) announced positive Phase II/III trial results for its COVID-19...
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...
Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...
Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial...
Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial
Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...
CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA...
CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...
Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial
Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...
Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for...
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject...
HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the...
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...
BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...
Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial
China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...
Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study
Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...
Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...
HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...